Colonic treatments and targets: Issues and opportunities

Journal of Drug Targeting

Volumn 17, Issue 5, 2009, Pages 335-363

  McConnell, Emma L ^a,b   Liu, Fang ^a   Basit, Abdul W ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b Merck Sharp & Dohme Limited   (United Kingdom)

Author keywords

Bacteria; Cancer; Chronotherapy; Colonic delivery; Fermentation; Gastrointestinal tract; Large intestine; Lymphatics; Microbiota; Peptides; Pharmacogenomics; Proteins; Ulcerative colitis; Vaccine

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; AZETIRELIN; BALSALAZIDE; CALCITONIN; CELECOXIB; CHLORAMPHENICOL; CLONAZEPAM; CYTOCHROME P450 ISOENZYME; CYTOTOXIC AGENT; DAIDZEIN; DIGOXIN; DRUG METABOLIZING ENZYME; FLUCYTOSINE; FLUOROURACIL; GLYCOPROTEIN P; HESPERIDIN; INFLIXIMAB; INSULIN; ISOSORBIDE DINITRATE; LEVAMISOLE; LEVODOPA; MESALAZINE; METHAMPHETAMINE; PLACEBO; PROBIOTIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SALAZOSULFAPYRIDINE; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; AUTACOID; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; NANOPARTICLE; PEPTIDE; PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CELL MEMBRANE TRANSPORT; CHRONOTHERAPY; CLINICAL TRIAL; COLON CANCER; COLON DISEASE; COLON MUCOSA; COLON TUMOR; COLORECTAL CANCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG METABOLISM; DRUG TARGETING; ENTERITIS; GENE MUTATION; HUMAN; ILEITIS; NONHUMAN; PARASITOSIS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; ANIMAL; BACTERIUM; COLON; DRUG EFFECT; INTESTINE ABSORPTION; LYMPHOID TISSUE; METABOLISM; MICROBIOLOGY; PH; PHARMACOGENETICS; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIA; COLON; COLONIC DISEASES; COLONIC NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEN-ION CONCENTRATION; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTESTINAL ABSORPTION; LYMPHOID TISSUE; NANOPARTICLES; PEPTIDES; PHARMACOGENETICS; PROBIOTICS; PROTEINS;

EID: 69149099286     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860902839502     Document Type: Review

References (283)

1. Abu Shamat M. (1993). The role of the gastrointestinal microflora in the metabolism of drugs. Int J Pharm, 97, 1-13.
2. Abu Shamat MS, Beckett AH. (1983). Glyceryl trinitrate: metabolism by the intestinal flora. J Pharm Pharmacol, 35, 71P.
3. Adkin DA, Davis SS, Sparrow RA, Wilding IR. (1993). Colonic transit of different sized tablets in healthy subjects. J Control Release, 23, 147-156.
4. Adkin DA, Davis SS, Sparrow RA, Huckle PD, Phillips AJ, Wilding IR. (1995a). The effect of different concentrations of mannitol in solution on small intestinal transit: implications for drug absorption. Pharm Res, 12, 393-396.
5. Adkin DA, Davis SS, Sparrow RA, Huckle PD, Phillips AJ, Wilding IR. (1995b). The effects of pharmaceutical excipients on small intestinal transit. Br J Clin Pharmacol, 39, 381-387.
6. Adkin DA, Davis SS, Sparrow RA, Huckle PD, Wilding IR. (1995c). The effect of mannitol on the oral bioavailability of cimetidine. J Pharm Sci, 84, 1405-1409.
7. Al-Saidan SM, Krishnaiah YS, Satyanarayana V, Rao GS. (2005). In vitro and in vivo evaluation of guar gum-based matrix tablets of rofecoxib for colonic drug delivery. Curr Drug Deliv, 2, 155-163.
8. Amorij JP, Westra TA, Hinrichs WL, Huckriede A, Frijlink HW. (2007). Towards an oral influenza vaccine: comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model. Vaccine, 26, 67-76.
9. Antonin KH, Bieck P, Scheurlen M, Jedrychowski M, Malchow H. (1985). Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing. Br J Clin Pharmacol, 19(Suppl. 2), 137S-142S.
10. Ashiru DA, Patel R, Basit AW. (2008). Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. Pharm Res, 25, 2327-2333.
11. Atuma C, Strugala V, Allen A, Holm L. (2001). The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol, 280, G922-G929.
12. Bando H, McGinity JW. (2006a). Physicochemical properties of enteric films prepared from aqueous dispersions and organic solutions. Int J Pharm, 313, 43-48.
13. Bando H, McGinity JW. (2006b). Relationship between drug dissolution and leaching of plasticizer for pellets coated with an aqueous Eudragit((R)) S100: L100 dispersion. Int J Pharm, 323, 11-17.
14. Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD, Hing M, Wettstein AR, Field A. (2002). Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol, 17, 135-139.
15. Barone JA, Jessen LM, Colaizzi JL, Bierman RH. (1994). Cisapride: a gastrointestinal prokinetic drug. Ann Pharmacother, 28, 488-500.
16. Basit AW. (2005). Advances in colonic drug delivery. Drugs, 65, 1991-2007.
17. Basit AW, Lacey LF. (2001). Colonic metabolism of ranitidine: implications for its delivery and absorption. Int J Pharm, 227, 157-165.
18. Basit AW, Newton JM, Short MD, Waddington WA, Ell PJ, Lacey LF. (2001). The effect of polyethylene glycol 400 on gastrointestinal transit: implications for the formulation of poorly-water soluble drugs. Pharm Res, 18, 1146-1150.
19. Basit AW, Newton JM, Lacey LF. (2002). Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora. Int J Pharm, 237, 23-33.
20. Basit AW, Short MD, McConnell EL. (2009). Microbiota-triggered colonic delivery: robustness of the polysaccharide approach in the fed state in man. J Drug Target, 17, 64-71.
21. Bauditz J, Wedel S, Lochs H. (2002). Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut, 50, 196-200.
22. Bayat A, Dorkoosh FA, Dehpour AR, Moezi L, Larijani B, Junginger HE, Rafiee-Tehrani M. (2008). Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies. Int J Pharm, 356, 259-266.
23. Becerra CR, Frenkel EP, Ashfaq R, Gaynor RB. (2003). Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a phase II study. Int J Cancer, 105, 868-872.
24. Bechgaard H, Ladefoged K. (1978). Distribution of pellets in the gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets. J Pharm Pharmacol, 30, 690-692.
25. Berggren S, Gall C, Wollnitz N, Ekelund M, Karlbom U, Hoogstraate J, Schrenk D, Lennernas H. (2007). Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm, 4, 252-257.
26. Bergheim I, Bode C, Parlesak A. (2005a). Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma. BMC Gastroenterol, 5, 34.
27. Bergheim I, Bode C, Parlesak A. (2005b). Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa. BMC Clin Pharmacol, 5, 4.
28. Bertran X, Mane J, Fernandez-Banares F, Castella E, Bartoli R, Ojanguren I, Esteve M, Gassull MA. (1996). Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis. Gut, 38, 899-904.
29. Besselink MGH, Van Santvoort HC, Buskens E, Boermeester MA, Van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, Van Ramshorst B, Witteman BJM, Rosman C, Ploeg RJ, Brink MA, Schaapherder AFM, Dejong CHC, Wahab PJ, Van Laarhoven CJHM, Van Der Harst E, Van Eijck CHJ, Cuesta MA, Akkermans LMA, Gooszen HG. (2008). Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo- controlled trial. The Lancet, 371, 651-659.
30. Bhavsar MD, Amiji MM. (2008). Oral IL-10 gene delivery in a microsphere- based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther, 15, 1200-1209.
31. Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, De Waziers I. (2007). Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics, 17, 731-742.
32. Blokzijl H, Vander Borght S, Bok LI, Libbrecht L, Geuken M, Van Den Heuvel FA, Dijkstra G, Roskams TA, Moshage H, Jansen PL, Faber KN. (2007). Decreased P-glycoprotein (P-gp/ MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm Bowel Dis, 13, 710-720.
33. Bode H, Brendel E, Ahr G, Fuhr U, Harder S, Staib AH. (1996). Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine. Eur J Clin Pharmacol, 50, 195-201.
34. Bogentoft C, Alpsten M, Ekenved G. (1984). Absorption of acetylsalicylic acid from enteric-coated tablets in relation to gastric emptying and in-vivo disintegration. J Pharm Pharmacol, 36, 350-351.
35. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, Van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler, L. (2006). A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol, 4, 754-1749
36. Brockmeier D, Grigoleit HG, Leonhardt H. (1985). Absorption of glibenclamide from different sites of the gastro-intestinal tract. Eur J Clin Pharmacol, 29, 193-197.
37. Brown RL, Gibson JA, Sladen GE, Hicks B, Dawson AM. (1974). Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. Gut, 15, 999-1004.
38. Brunner M, Assandri R, Kletter K, Tschurlovits M, Corrado ME, Villa R, Eichler HG, Muller M. (2003). Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther, 17, 395-402.
39. Brunner M, Lackner E, Exler PS, Fluiter HC, Kletter K, Tschurlovits M, Dudczak R, Eichler HG, Muller M. (2006a). 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers. Aliment Pharmacol Ther, 23, 137-144.
40. Brunner M, Ziegler S, Di Stefano AF, Dehghanyar P, Kletter K, Tschurlovits M, Villa R, Bozzella R, Celasco G, Moro L, Rusca A, Dudczak R, Muller M. (2006b). Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol, 61, 31-38.
41. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica- Ihle E, Jeka S, Krueger K, Szechinski J, Alten R. (2008). Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. The Lancet, 371, 205-214.
42. Caldwell J, Hawksworth GM. (1973). The demethylation of methamphetamine by intestinal microflora. J Pharm Pharmacol, 25, 422-424.
43. Camilleri M. (2008). Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy. J Clin Gastroenterol, 42(Suppl. 3), S123-S125.
44. Canaparo R, Nordmark A, Finnstrom N, Lundgren S, Seidegard J, Jeppsson B, Edwards RJ, Boobis AR, Rane A. (2007). Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples. Basic Clin Pharmacol Toxicol, 100, 240-248.
45. Casella G, De Marco E, Monti C, Baldini V. (2006). The therapeutic role of thalidomide in inflammatory bowel disease. Minerva Gastroenterol Dietol, 52, 293-301.
46. Celasco G, Moro L, Bozzella R, Mangano K, Quattrocchi C, Aiello C, Donia M, Fagone P, Di Marco R. (2008). Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat. Dig Dis Sci, 53, 3170-3175.
47. Chan LMS, Lowes S, Hirst BH. (2004). The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci, 21, 25-51.
48. Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE. (1983). Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci, 28, 609-615.
49. Cherbut C. (2002). Inulin and oligofructose in the dietary fibre concept. Br J Nutr, 87(Suppl. 2), S159-S162.
50. Clarke GM, Newton JM, Short MD. (1993). Gastrointestinal transit of pellets of differing size and density. Int J Pharm, 100, 81-92.
51. Cole ET, Scott RA, Connor AL, Wilding IR, Petereit HU, Schminke C, Beckert T, Cade D. (2002). Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm, 231, 83-95.
52. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soule JC, Modgliani R, Touze Y, Catala P, Libersa C, Broly F, Affecti GDET. (2000). Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology, 118, 1025-1030.
53. Crociani F, Alessandrini A, Mucci MM, Biavati B. (1994). Degradation of complex carbohydrates by Bifidobacterium spp. Int J Food Microbiol, 24, 199-210.
54. Cummings JH, Englyst HN. (1987). Fermentation in the human large intestine and the available substrates. Am J Clin Nutr, 45, 1243-1255.
55. Cummings JH, Banwell JG, Segal I, Coleman N, Englyst HN, Macfarlane GT. (1990). The amount and composition of large bowel contents in man. Gastroenterology, 98, A408.
56. Cummings JH, Antoine JM, Azpiroz F, Bourdet-Sicard R, Brandtzaeg P, Calder PC, Gibson GR, Guarner F, Isolauri E, Pannemans D, Shortt C, Tuijtelaars S, Watzl B. (2004). PASSCLAIM-gut health and immunity. Eur J Nutr, 43(Suppl. 2), II118-II173.
57. Cutolo M, Straub RH. (2008). Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun Rev, 7, 23-228.
58. Das KM, Eastwood MA, Mcmanus JPA, Sircus W. (1973). Adverse reactions during salicylazosulfapyridine therapy and relation with drug-metabolism and acetylator phenotype. N Engl J Med, 289, 491-495.
59. Davis SS. (1989). Small intestinal transit. In: Hardy JG, Davis SS, Wilson CG. (eds.) Drug delivery to the gastrointestinal tract. Chichester, UK: Ellis Horwood Limited pp.49-61.
60. Davis SS, Hardy JG, Fara JW. (1986). Transit of pharmaceutical dosage forms through the small intestine. Gut, 27, 886-892.
61. Delomenie C, Fouix S, Longuemaux S, Brahimi N, Bizet C, Picard B, Denamur E, Dupret JM. (2001). Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol, 183, 3417-3427.
62. DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. (2002). Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol, 34, 385-396.
63. Devereux JE, Newton JM, Short MB. (1990). The influence of density on the gastrointestinal transit of pellets. J Pharm Pharmacol, 42, 500-501.
64. Dew MJ, Hughes PJ, Lee MG, Evans BK, Rhodes J. (1982). An oral preparation to release drugs in the human colon. Br J Clin Pharmacol, 14, 405-408.
65. Dew MJ, Ryder REJ, Evans N, Evans BK, Rhodes J. (1983). Colonic release of 5-amino salicylic-acid from an oral preparation in active ulcerative-colitis. Br J Clin Pharmacol, 16, 185-187.
66. Dobson CL, Davis SS, Chauhan S, Sparrow RA, Wilding IR. (1999). The effect of oleic acid on the human ileal brake and its implications for small intestinal transit of tablet formulations. Pharm Res, 16, 92-96.
67. Drewe J, Narjes H, Heinzel G, Brickl RS, Rohr A, Beglinger C. (2000). Absorption of lefradafiban from different sites of the gastrointestinal tract. Br J Clin Pharmacol, 50, 69-72.
68. Dull BJ, Salata K, Goldman P. (1987). Role of the intestinal flora in the acetylation of sulfasalazine metabolites. Biochem Pharmacol, 36, 3772-3774.
69. Ebel JP, Jay M, Beihn RM. (1993). An in vitro in vivo correlation for the disintegration and onset of drug release from enteric-coated pellets. Pharm Res, 10, 233-238.
70. Edwards C. (1997). Physiology of the colorectal barrier. Adv Drug Deliv Rev, 28, 173-190.
71. Elmer GW, Remmel RP. (1984). Role of the intestinal microflora in clonazepam metabolism in the rat. Xenobiotica, 14, 829-840.
72. Elsayed E, Becker RC. (2003). The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis, 15, 11-18.
73. Englund G, Rorsman F, Rönnblom A, Karlbom U, Lazorova L, Gråsjö J, Kindmark A, Artursson P. (2006). Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci, 29, 269-277.
74. Englund G, Jacobson A, Rorsman F, Artursson P, Kindmark A, Ronnblom A. (2007). Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and p (ABCB1). Inflamm Bowel Dis, 13, 291-297.
75. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. (1988). Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut, 29, 1035-1041.
76. Fadda HM, Basit AW. (2005). Dissolution of pH responsive formulations in media resembling intestinal fluids: bicarbonate versus phosphate buffers. J Drug Deliv Sci Technol, 15, 273-279.
77. Fadda HM, Hernández MC, Margetson DN, McAllister SM, Basit AW, Brocchini S, Suárez N. (2008a). The molecular interactions that influence the plasticizer dependent dissolution of acrylic polymer films. J Pharm Sci, 97, 3957-3971.
78. Fadda HM, Mohamed MA, Basit AW (2008b). Impairment of the in vitro drug release behaviour of oral modified release preparations in the presence of alcohol. Int J Pharm, 360, 171-176.
79. Fadda HM, McConnell EL, Short M, Basit AW. (2009). Meal-induced acceleration of tablet transit through the human small intestine. Pharm Res, 26, 356-360.
80. Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. (1989). pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther, 3, 605-613.
81. Fallingborg J, Christensen LA, Jacobsen BA, Rasmussen SN. (1993). Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci, 38, 1989-1993.
82. Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'toole D, Mahmud N, Keeling PW, Weir DG, Kelleher D. (2000). High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology, 118, 279-288.
83. Flach CF, Qadri F, Bhuiyan TR, Alam NH, Jennische E, Holmgren J, Lonnroth I. (2007). Differential expression of intestinal membrane transporters in cholera patients. FEBS Lett, 581, 3183-3188.
84. Ford D, Howard A, Hirst BH. (2003). Expression of the peptide transporter hPepT1 in human colon: a potential route for colonic protein nitrogen and drug absorption. Histochem Cell Biol, 119, 37-43.
85. Fuhr U, Staib AH, Harder S, Becker K, Liermann D, Schollnhammer G, Roed IS. (1994). Absorption of ipsapirone along the human gastrointestinal tract. Br J Clin Pharmacol, 38, 83-86.
86. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'neil DA, Macfarlane GT. (2005). Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut, 54, 242-249.
87. Gao SQ, Lu ZR, Kopeckova P, Kopecek J. (2007). Biodistribution and pharmacokinetics of colon-specific HPMA copolymer-9- aminocamptothecin conjugate in mice. J Control Release, 117, 179-185.
88. Gao SQ, Sun Y, Kopeckova P, Peterson CM, Kopecek J. (2008). Pharmacokinetic modeling of absorption behavior of 9-aminocamptothecin (9-AC) released from colon-specific HPMA copolymer-9-AC conjugate in rats. Pharm Res, 25, 218-226.
89. Gibson GR, Macfarlane S, Cummings JH. (1990). The fermentability of polysaccharides by mixed human faecal bacteria in relation to their suitability as bulk-forming laxatives. Lett Appl Microbiol, 11, 251-254.
90. Gibson SA, Mcfarlan C, Hay S, Macfarlane GT. (1989). Significance of microflora in proteolysis in the colon. Appl Environ Microbiol, 55, 679-683.
91. Gill S, Sinicrope FA. (2005). Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? Semin Oncol, 32, 24-34.
92. Gingell R, Bridges JW, Williams RT. (1971). The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat. Xenobiotica, 1, 143-156.
93. Gleiter CH, Antonin KH, Bieck P, Godbillon J, Schonleber W, Malchow H. (1985). Colonoscopy in the investigation of drug absorption in healthy volunteers. Gastrointest Endosc, 31, 71-73.
94. Godbillon J, Evard D, Vidon N, Duval M, Schoeller JP, Bernier JJ, Hirtz J. (1985). Investigation of drug absorption from the gastrointestinal tract of man. III. Metoprolol in the colon. Br J Clin Pharmacol, 19(Suppl. 2), 113S-118S. (Pubitemid 16193630)
95. Goldin BR, Peppercorn MA, Goldman P. (1973). Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat. J Pharmacol Exp Ther, 186, 160-166.
96. Gorbach SL, Plaut AG, Nahas L, Weinstein L, Spanknebel G, Levitan R. (1967). Studies of intestinal microflora. II. Microorganisms of the small intestine and their relations to oral and fecal flora. Gastroenterology, 53, 856-867.
97. Gotch F, Nadell J, Edelman IS. (1957). Gastrointestinal water and electrolytes. IV. The equilibration of deuterium oxide (D2O) in gastrointestinal contents and the proportion of total body water (T.B.W) in the gastrointestinal tract. J Clin Investig, 36, 289-296.
98. Goto T, Tomizawa N, Kobayashi E, Fujimura A. (2004). A comparative pharmacology study between the intracolonic and oral routes of 5-FU administration in a colon cancer-bearing Yoshida sarcoma rat model. J Pharmacol Sci, 95, 163-173.
99. Green JT, Mckirdy HC, Rhodes J, Thomas GA, Evans BK. (1999). Intraluminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel. Eur J Gastroenterol Hepatol, 11, 1299-1304.
100. Green JT, Richardson C, Marshall RW, Rhodes J, Mckirdy HC, Thomas GA, Williams GT. (2000). Nitric oxide mediates a therapeutic effect of nicotine in ulcerative colitis. Aliment Pharmacol Ther, 14, 1429-1434.
101. Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J. (2005). Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol, 70, 695-699.
102. Hardy JG, Wilson CG, Wood E. (1985). Drug delivery to the proximal colon. J Pharm Pharmacol, 37, 874-877.
103. Hardy JG, Healey JN, Lee SW, Reynolds JR. (1987). Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet. Aliment Pharmacol Ther, 1, 209-216.
104. Harris BE, Manning BW, Federle TW, Diasio RB. (1986). Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob Agents Chemother, 29, 44-48.
105. Hartemink R, Van Laere KMJ, Mertens AKC, Rombouts FM. (1996). Fermentation of xyloglucan by intestinal bacteria. Anaerobe, 2, 223-230.
106. Haupt S, Gil E, Tirosh R, Klinger E, Gad A, Rubinstein A. (2002). Regional peptide uptake study in the rat intestinal mucosa: glatiramer acetate as a model drug. Pharm Res, 19, 832-837.
107. Haupt S, Zioni T, Gati I, Kleinstern J, Rubinstein A. (2006). Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. Eur J Pharm Sci, 28, 204-211.
108. Hawkey C, Gassull M, Lauritsen K, Martin F, Omorain C, Raskmadsen J, Wright J, Dube L, Rountree L, Broutman L. (1994). Efficacy of zileuton, a 5-lipoxygenase inhibitor, in the maintenance of remission in patients with ulcerative-colitis. Gastroenterology, 106, A697.
109. Hebden JM, Wilson CG, Spiller RC, Gilchrist PJ, Blackshaw E, Frier ME, Perkins AC. (1999). Regional differences in quinine absorption from the undisturbed human colon assessed using a timed release delivery system. Pharm Res, 16, 1087-1092.
110. Hill MJ, Drasar BS. (1975). The normal colonic bacterial flora. Gut, 16, 318-323.
111. Hinderling PH, Karara AH, Tao B, Pawula M, Wilding I, Lu M. (2007). Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract. J Clin Pharmacol, 47, 19-25.
112. Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, Van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S. (2005). Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther, 22, 613-626.
113. Hoffstetter W, Ortega A, Chiang M, Paik P, Beart RW. (2001). Effects of topical tumoricidal agents on port-site recurrence of colon cancer: an experimental study in rats. J Laparoendosc Adv Surg Tech A, 11, 9-12.
114. Holt R. (1967). The bacterial degradation of chloramphenicol. Lancet, 1, 1259-1260.
115. Hopkins MJ, Englyst HN, Macfarlane S, Furrie E, Macfarlane GT, Mcbain AJ. (2003). Degradation of cross-linked and non-crosslinked arabinoxylans by the intestinal microbiota in children. Appl Environ Microbiol, 69, 6354-6360.
116. Hsyu PH, Pritchard JF, Bozigian HP, Lloyd TL, Griffin RH, Shamburek R, Krishna G, Barr WH. (1994). Comparison of the pharmacokinetics of an ondansetron solution ( 8 mg) when administered intravenously, orally, to the colon, and to the rectum. Pharm Res, 11, 156-159.
117. Ibekwe VC, Liu F, Fadda HM, Khela MK, Evans DF, Parsons GE, Basit AW. (2006). An investigation into the in vivo performance variability of pH responsive polymers for ileo-colonic drug delivery using gamma scintigraphy in humans. J Pharm Sci, 95, 2760-2766.
118. Ibekwe VC, Fadda HM, McConnell EL, Khela MK, Evans DF, Basit AW. (2008a). Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res, 25, 1828-1835.
119. Ibekwe VC, Khela MK, Evans DF, Basit AW. (2008b). A new concept in colonic drug targeting: a combined pH-responsive and bacterially- triggered drug delivery technology. Aliment Pharmacol Ther, 28, 911-916.
120. Illum L. (1998). Chitosan and its use as a pharmaceutical excipient. Pharm Res, 15, 1326-1331.
121. Ingram JR, Rhodes J, Evans BK, Thomas GA. (2008). Nicotine enemas for active Crohn's colitis: an open pilot study. Gastroenterol Res Pract, 2008, 237185.
122. Jain SK, Jain A. (2008). Target-specific drug release to the colon. Expert Opin Drug Deliv, 5, 483-498.
123. Kachel G, Ruppin H, Hagel J, Barina W, Meinhardt M, Domschke W. (1986). Human intestinal motor activity and transport: effects of a synthetic opiate. Gastroenterology, 90, 85-93.
124. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A, Arakawa Y. (2004). Randomized placebo-controlled trial assessing the effect of bifidobacteria- fermented milk on active ulcerative colitis. Aliment Pharmacol Ther, 20, 1133-1141.
125. Katsuma M, Watanabe S, Takemura S, Sako K, Sawada T, Masuda Y, Nakamura K, Fukui M, Connor AL, Wilding IR. (2004). Scintigraphic evaluation of a novel colon-targeted delivery system (CODES) in healthy volunteers. J Pharm Sci, 93, 1287-1299.
126. Katsuma M, Watanabe S, Kawai H, Takemura S, Sako K. (2006). Effects of absorption promoters on insulin absorption through colontargeted delivery. Int J Pharm, 307, 156-162.
127. Kenyon CJ, Cole ET, Wilding IR. (1994). The effect of food on the in- vivo behavior of enteric-coated starch capsules. Int J Pharm, 112, 207-213.
128. Khan MZI, Prebeg Z, Kurjakovic N. (1999). A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers-I. Manipulation of drug release using Eudragit (R) L100-55 and Eudragit (R) S100 combinations. J Control Release, 58, 215-222.
129. Khosla R, Davis SS. (1989). Gastric emptying and small and large bowel transit of non-disintegrating tablets in fasted subjects. Int J Pharm, 52, 1-10.
130. Kim H, Huh J, Jeon H, Choi D, Han J, Kim Y, Jung Y. (2009). N,N'- Bis(5-aminosalicyl)-L-cystine is a potential colon-specific 5-aminosalicylic acid prodrug with dual therapeutic effects in experimental colitis. J Pharm Sci, 98, 159-168.
131. Kim RB. (2002). Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev, 34, 47-54.
132. Kitamura S, Sugihara K, Kuwasako M, Tatsumi K. (1997). The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. J Pharm Pharmacol, 49, 253-256.
133. Koch KM, Parr AF, Tomlinson JJ, Sandefer EP, Digenis GA, Donn KH, Powell JR. (1993). Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time. Pharm Res, 10, 1027-1030.
134. Koch RL, Chrystal EJ, Beaulieu BB, Jr, Goldman P. (1979). Acetamide-a metabolite of metronidazole formed by the intestinal flora. Biochem Pharmacol, 28, 3611-3615.
135. Koch RL, Beaulieu BB, Jr, Goldman P. (1980). Role of the intestinal flora in the metabolism of misonidazole. Biochem Pharmacol, 29, 3281-3284.
136. Kool M, Van Der Linden M, De Haas M, Scheffer GL, De Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas, F, Borst P. (1999). MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA, 96, 6914-6919.
137. Kramer WG. (1994). Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. J Clin Pharmacol, 34, 1218-1221.
138. Krishnaiah YS, Seetha Devi A, Nageswara Rao L, Bhaskar Reddy PR, Karthikeyan RS, Satyanarayana V. (2001). Guar gum as a carrier for colon specific delivery; influence of metronidazole and tinidazole on in vitro release of albendazole from guar gum matrix tablets. J Pharm Pharm Sci, 4, 235-243.
139. Krishnaiah YS, Indira Muzib Y, Srinivasa Rao G, Bhaskar P, Satyanarayana V. (2002a). Design and in vitro evaluation of oral colon targeted drug delivery systems for tinidazole. J Drug Target, 10, 579-584. (Pubitemid 36124357)
140. Krishnaiah YS, Bhaskar Reddy PR, Satyanarayana V, Karthikeyan RS. (2002b). Studies on the development of oral colon targeted drug delivery systems for metronidazole in the treatment of amoebiasis. Int J Pharm, 236, 43-55. (Pubitemid 34219372)
141. Krishnaiah YSR, Satyanarayana V, Kumar BD, Karthikeyan RS, Bhaskar P. (2003a). In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets. Eur J Pharm Sci, 19, 355-362. (Pubitemid 36952397)
142. Krishnaiah YS, Muzib YI, Bhaskar P, Satyanarayana V, Latha K. (2003b). Pharmacokinetic evaluation of guar gum-based colontargeted drug delivery systems of tinidazole in healthy human volunteers. Drug Deliv, 10, 263-268. (Pubitemid 37494140)
143. Krishnaiah YS, Veer Raju P, Dinesh Kumar B, Satyanarayana V, Karthikeyan RS, Bhaskar P. (2003c). Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of mebendazole in healthy volunteers. J Control Release, 88, 95-103. (Pubitemid 36173955)
144. Krishnaiah YS, Indira Muzib Y, Bhaskar P. (2003d). In vivo evaluation of guar gum-based colon-targeted drug delivery systems of ornidazole in healthy human volunteers. J Drug Target, 11, 109-115. (Pubitemid 36869184)
145. Krishnaiah YS, Muzib YI, Rao GS, Bhaskar P, Satyanarayana V. (2003e). Studies on the development of colon targeted oral drug delivery systems for ornidazole in the treatment of amoebiasis. Drug Deliv, 10, 111-117.
146. Krishnaiah YS, Veer Raju P, Dinesh Kumar B, Jayaram B, Rama B, Raju V, Bhaskar P. (2003f). Pharmacokinetic evaluation of guar gum-based colon-targeted oral drug delivery systems of metronidazole in healthy volunteers. Eur J Drug Metab Pharmacokinet, 28, 287-294. (Pubitemid 38076274)
147. Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, Kuitunen M. (2008). Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo- controlled trial. Pediatrics, 122, 8-12.
148. Kusuhara H, Sugiyama Y. (2002). Role of transporters in the tissueselective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release, 78, 43-54.
149. Lamprecht A, Schafer U, Lehr CM. (2001). Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res, 18, 788-793.
150. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. (2005). Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther, 315, 196-202.
151. Langman JM, Rowland R. (1986). The number and distribution of lymphoid follicles in the human large intestine. J Anat, 149, 189-194.
152. Langman JM, Rowland R. (1992). Density of lymphoid follicles in the rectum and at the anorectal junction. J Clin Gastroenterol, 14, 81-84.
153. Lazzerini M, Martelossi S, Marchetti F, Scabar A, Bradaschia F, Ronfani L, Ventura A. (2007). Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther, 25, 419-427.
154. Lee L, Hossain M, Wang Y, Sedek G. (2004a). Absorption of rivastigmine from different regions of the gastrointestinal tract in humans. J Clin Pharmacol, 44, 599-604.
155. Lee NK, Choi SH, Park SH, Park EK, Kim DH. (2004b). Antiallergic activity of hesperidin is activated by intestinal microflora. Pharmacology, 71, 174-180.
156. Lehmann K, Brogmann B, Kenyon CJ, Wilding IR. (1997). The in vivo behaviour of enteric naproxen tablets coated with an aqueous dispersion of methacrylic acid copolymer. Stp Pharma Sci, 7, 463-468.
157. Lennernas H, Abrahamsson B. (2005). The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol, 57, 273-285.
158. Lennernas H, Nilsson D, Aquilonius SM, Ahrenstedt O, Knutson L, Paalzow LK. (1993). The effect of l-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br J Clin Pharmacol, 35, 243-250.
159. Lindenbaum J, Rund DG, Butler VP, Jr, Tse-Eng D, Saha JR. (1981). Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med, 305, 789-794.
160. Liu F, Lizio R, Meier C, Petereit H-U, Blakey P, Basit AW. (2009). A novel concept in enteric coating: a double-coating system providing rapid drug release in the proximal small intestine. J Control Release, 133(2), 119-124.
161. Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'haens G, Malaise M, Belaiche J. (2002). A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism. Scand J Gastroenterol, 37, 818-824.
162. Louis E, El Ghoul Z, Vermeire S, Dall'ozzo S, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Colombel JF, Watier H. (2004). Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther, 19, 511-519.
163. Mallon P, Mckay D, Kirk S, Gardiner K. (2007). Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev, CD005573.
164. Marathe PH, Salazar DE, Greene DS, Brennan J, Shukla UA, Barbhaiya RH. (1995). Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans. Pharm Res, 12, 1716-1721.
165. Mariani PP, Van Pelt JF, Ectors N, Topal B, D'hoore A, Penninckx F. (2002). Rectal washout with cytotoxic solution can be extended to the whole colon. Br J Surg, 89, 1540-1544.
166. McConnell EL, Fadda HM, Basit AW. (2008a). Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm, 364(2), 213-226.
167. McConnell EL, Murdan S, Basit AW. (2008b). An investigation into the digestion of chitosan (noncrosslinked and crosslinked) by human colonic bacteria. J Pharm Sci, 97(9): 3820-3829.
168. McConnell EL, Basit AW, Murdan S. (2008c). Colonic antigen administration induces significantly higher humoral levels of colonic and vaginal IgA, and serum IgG compared to oral administration. Vaccine, 26, 639-646.
169. McConnell EL, Short MD, Basit AW. (2008d). An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man. J Control Release, 130, 154-160.
170. McGirr MEA, McAllister SM, Peters EE, Vickers AW, Parr AF, Basit AW. (2009). The use of the InteliSite® Companion device to deliver mucoadhesive polymers to the dog colon. Eur J Pharm Sci, 36(4-5): 386-391.
171. McGrath J, Mcdonald JW, Macdonald JK. (2004). Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst Rev, CD004722.
172. Meier Y, Eloranta JJ, Darimont J, Ismair MG, Hiller C, Fried M, Kullak- Ublick GA, Vavricka SR. (2007). Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos, 35, 590-594.
173. Meissner Y, Ubrich N, El Ghazouani F, Maincent P, Lamprecht A. (2007). Low molecular weight heparin loaded pH-sensitive microparticles. Int J Pharm, 335, 147-153.
174. Meuldermans W, Hendrickx J, Mannens G, Lavrijsen K, Janssen C, Bracke J, Le Jeune L, Lauwers W, Heykants J. (1994). The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab Dispos, 22, 129-138.
175. Meyer UA, Zanger UM. (1997). Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann Rev Pharmacol Toxicol, 37, 269-296.
176. Miner P, Wedel M, Bane B, Bradley J. (2004). An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther, 19, 281-286.
177. Miner PB, Jr, Geary RS, Matson J, Chuang E, Xia S, Baker BF, Wedel MK. (2006a). Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther, 23, 1427-1434.
178. Miner PB, Jr, Wedel MK, Xia, S, Baker BF. (2006b). Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther, 23, 1403-1413.
179. Mirbagheri SA, Nezami BG, Assa S, Hajimahmoodi M. (2008). Rectal administration of d-alpha tocopherol for active ulcerative colitis: a preliminary report. World J Gastroenterol, 14, 5990-5995.
180. Mohanraj VJ, Chen Y. (2006). Nanoparticles-a review. Tropical J Pharm Res, 5, 561-573.
181. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, Yokoi T. (2008). Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos, 36, 1461-1464.
182. Nakase H, Okazaki K, Tabata Y, Uose S, Ohana M, Uchida K, Nishi T, Debreceni A, Itoh T, Kawanami C, Iwano M, Ikada Y, Chiba T. (2001). An oral drug delivery system targeting immuneregulating cells ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis. J Pharmacol Exp Ther, 297, 1122-1128.
183. Nakase H, Okazaki K, Tabata Y, Chiba T. (2003). Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease. J Gastroenterol, 38(Suppl. 15), 59-62.
184. Noguera Aguilar JF, Amengual Antich I, Moron Canis JM, Plaza Martinez A, Martinez Corcoles JA, Tortajada Collado C, Pujol Tugores JJ. (2005). Effect of rofecoxib on colon chemical carcinogenesis at colonic anastomotic area in the rat. Rev Esp Enferm Dig, 97, 405-415.
185. Nugent SG, Kumar D, Rampton DS, Yazaki E, Evans DF. (2000). Gut pH and transit time in ulcerative colitis appear sufficient for complete dissolution of pH-dependent mesalazine-containing capsules. Gut, 46, A9.
186. Nyman M. (2002). Fermentation and bulking capacity of indigestible carbohydrates: the case of inulin and oligofructose. Br J Nutr, 87(Suppl. 2), S163-S168.
187. O'Driscoll CM. (2002). Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci, 15, 405-415.
188. Ogra PL, Karzon DT. (1969). Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine. J Immunol, 102, 1423-1430.
189. Ohtani T, Hiroi A, Sakurane M, Furukawa F. (2003). Slow acetylator genotypes as a possible risk factor for infectious mononucleosislike syndrome induced by salazosulfapyridine. Br J Dermatol, 148, 1035-1039.
190. Okuda H, Ogura K, Kato A, Takubo H, Watabe T. (1998). A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Therap, 287, 791-799.
191. Onizuka Y, Murase K, Furusu H, Isomoto H, Mizuta Y, Takeshima F, Makiyama K, Kohno S. (2000). Effect of intrarectal prostaglandin E-2 analogue (enprostil) on trinitrobenzenesulphonic acidinduced colitis in rats. J Int Med Res, 28, 28-35.
192. Oo C, Snell P, Barrett J, Dorr A, Liu B, Wilding I. (2003). Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules. Int J Pharm, 257, 297-299.
193. Palframan RJ, Gibson GR, Rastall RA. (2003). Carbohydrate p of Bifidobacterium species isolated from the human gut. Curr Issues Intest Microbiol, 4, 71-75.
194. Papagiorgis P, Oikonomakis I, Karapanagiotou I, Wexner SD, Nikiteas N. (2006). The impact of tumor location on the histopathologic expression of colorectal cancer. J BUON, 11, 317-321.
195. Pastorelli L, Saibeni S, Spina L, Signorelli C, Celasco G, De Franchis R, Vecchi M. (2008). Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther, 28, 581-588.
196. Patel RT, Pall AA, Adu D, Keighley MR. (1995). Circulating soluble adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol, 7, 1037-1041.
197. Pellequer Y, Weissenborn V, Lamprecht A. (2007). Decreased drug penetration in inflamed tissue related to changed mucosal metabolism in experimental colitis. J Pharm Sci, 96, 2145-2153.
198. Peppercorn M, Das K, Elson C, Geraci K, Robinson M, Rubin A, Salzberg B, Wruble L, Dube L, Rountree L, Broutman L. (1994). Zileuton, a 5-Lipoxygenase Inhibitor, in the treatment of active ulcerative-colitis-a double-blind, placebo-controlled trial. Gastroenterology, 106, A751.
199. Peppercorn MA, Goldman P. (1972). The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther, 181, 555-562.
200. Pertuit D, Moulari B, Betz T, Nadaradjane A, Neumann D, Ismaïli L, Refouvelet B, Pellequer Y, Lamprecht A. (2007). 5-Amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release, 123, 211-218.
201. Piche T, Barbara G, Aubert P, Bruley Des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche JP, Neunlist M. (2009). Impaired intestinal barrier integrity in the colon of irritable bowel syndrome patients: involvement of soluble mediators. Gut, 58, 196-201.
202. Podczeck F, Course NC, Newton JM, Short MB. (2007a). The influence of non-disintegrating tablet dimensions and density on their gastric emptying in fasted volunteers. J Pharm Pharmacol, 59, 23-27.
203. Podczeck F, Mitchell CL, Newton JM, Evans D, Short MB. (2007b). The gastric emptying of food as measured by gamma-scintigraphy and electrical impedance tomography (EIT) and its influence on the gastric emptying of tablets of different dimensions. J Pharm Pharmacol, 59, 1527-1536.
204. Prakash O, Medhi B, Saikia UN, Pandhi P. (2008). Effect of different doses of thalidomide in experimentally induced inflammatory bowel disease in rats. Basic Clin Pharmacol Toxicol, 103, 9-16. (Pubitemid 351874535)
205. Quigley EM. (2008). What is the evidence for the use of probiotics in functional disorders? Curr Gastroenterol Rep, 10, 379-384.
206. Rafii F, Sutherland JB, Hansen EB, Jr, Cerniglia, CE. (1997). Reduction of nitrazepam by Clostridium leptuma nitroreductase-producing bacterium isolated from the human intestinal tract. Clin Infect Dis, 25(Suppl. 2), S121-S122.
207. Rafii F, Hotchkiss C, Heinze TM, Park M. (2004). Metabolism of daidzein by intestinal bacteria from rhesus monkeys (Macaca mulatta). Comp Med, 54, 165-169.
208. Rajilic-Stojanovic M, Smidt H, De Vos WM. (2007). Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol, 9, 2125-2136. (Pubitemid 47222128)
209. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. (1999). Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet, 354, 635-639.
210. Reynolds JC. (1989). Prokinetic agents: a key in the future of gastroenterology. Gastroenterol Clin North Am, 18, 437-457.
211. Ricart E, Taylor WR, Loftus EV, O'kane D, Weinshilboum RM, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. (2002). N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol, 97, 1763-1768.
212. Riley SA, Kim M, Sutcliffe F, Rowiand M, Turnberg LA. (1992). Absorption of polar drugs following caecal instillation in healthy volunteers. Aliment Pharmacol Ther, 6, 701-706.
213. Rochet V, Bernalier A. (1997). Utilization of algal polysaccharides by human colonic bacteria, in axenic culture or in association with hydrogenotrophic microorganisms. Reprod Nutr Dev, 37, 221-229.
214. Ross AH, Eastwood MA, Brydon WG, Anderson JR, Anderson DM. (1983). A study of the effects of dietary gum arabic in humans. Am J Clin Nutr, 37, 368-375.
215. Safdi AV. (2005). Determination of mesalazine in whole or partial mesalamine delayed-release tablets recovered from fecal samples of healthy volunteers. Am J Gastroenterol, 100, S159.
216. Saibeni S, Spina L, Pastorelli L, De Franchis R, Moro L, Villa R, Bozzella R, Celasco G, Vecchi M. (2006). Safety and efficacy of oral, colonic-release, Low Molecular Weight Heparin-MMXTM for the treatment of mild to moderate left-sided ulcerative colitis: preliminary reports of a pilot study. Gastroenterology, 130, AGA Abstract W1227.
217. Sakkinen M, Marvola J, Kanerva H, Lindevall K, Ahonen A, Marvola M. (2006). Are chitosan formulations mucoadhesive in the human small intestine? An evaluation based on gamma scintigraphy. Int J Pharm, 307, 285-291.
218. Salyers AA, West SE, Vercellotti JR, Wilkins TD. (1977). Fermentation of mucins and plant polysaccharides by anaerobic bacteria from the human colon. Appl Environ Microbiol, 34, 529-533.
219. Salyers AA, Palmer JK, Wilkins TD. (1978). Degradation of polysaccharides by intestinal bacterial enzymes. Am J Clin Nutr, 31, S128-S130.
220. Sasaki I, Tamura T, Shibakawa T, Fujita T, Murakami M, Yamamoto A, Muranishi S. (1997). Metabolism of azetirelin, a new thyrotropin- releasing hormone (TRH) analogue, by intestinal microorganisms. Pharm Res, 14, 1004-1007.
221. Sasaki S, Hirata I, Maemura K, Hamamoto N, Murano M, Toshina K, Katsu K. (2000). Prostaglandin E-2 inhibits lesion formation in dextran sodium sulphate-induced colitis in rats and reduces the levels of mucosal inflammatory cytokines. Scand J Immunol, 51, 23-28.
222. Schiller C, Frohlich CP, Geissman T, Siegmund W, Monnikes H, Hosten N, Weitschies W. (2005). Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Therap, 22, 971-979.
223. Schneider H, Simmering R, Hartmann L, Pforte H, Blaut M. (2000). Degradation of quercetin-3-glucoside in gnotobiotic rats associated with human intestinal bacteria. J Appl Microbiol, 89, 1027-1037.
224. Schroeder KW, Tremaine WJ, Ilstrup DM. (1987). Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med, 317, 1625-1629.
225. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A. (1999). MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med, 5, 1048-1051.
226. Schulze JD, Waddington WA, Eli PJ, Parsons GE, Coffin MD, Basit AW. (2003). Concentration-dependent effects of polyethylene glycol 400 on gastrointestinal transit and drug absorption. Pharm Res, 20, 1984-1988.
227. Schulze JD, Ashiru DA, Khela MK, Evans DF, Patel R, Parsons GE, Coffin MD, Basit AW. (2006). Impact of formulation excipients on human intestinal transit. J Pharm Pharmacol, 58, 821-825.
228. Schulze JDR, Peters EE, Vickers AW, Staton JS, Coffin MD, Parsons GE, Basit AW. (2005). Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. Int J Pharm, 300, 67-75.
229. Seidegård J, Nyberg L, Borgå O. (2008). Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole. Eur J Pharm Sci, 35, 264-270.
230. Seithel A, Karlsson J, Hilgendorf C, Bjorquist A, Ungell AL. (2006). Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur J Pharm Sci, 28, 291-299.
231. Shu YZ, Kingston DG, Van Tassell RL, Wilkins TD. (1991). Metabolism of levamisole, an anti-colon cancer drug, by human intestinal bacteria. Xenobiotica, 21, 737-750.
232. Siew LF, Man SM, Newton JM, Basit AW. (2004). Amylose formulations for drug delivery to the colon: a comparison of two fermentation models to assess colonic targeting performance in vitro. Int J Pharm, 273, 129-134.
233. Simonsen L, Hovgaard L, Mortensen PB, Brondsted H. (1995). Dextran hydrogels for colon-specific delivery. V. Degradation in human intestinal incubation models. Eur J Pharm Sci, 3, 329-337.
234. Sinha A, Ball BJ, Connor AL, Nightingale J, Wilding IR. (2003). Intestinal performance of two mesalamine formulations in patients with active ulcerative colitis as assessed by gamma scintigraphy. Pract Gastroenterol, 27, 56-69.
235. Sinha V, Singh A, Kumar RV, Singh S, Kumria R, Bhinge J. (2007). Oral colon-specific drug delivery of protein and peptide drugs. Crit Rev Ther Drug Carrier Syst, 24, 63-92.
236. Sinha VR, Kumria R. (2003). Microbially triggered drug delivery to the colon. Eur J Pharm Sci, 18, 3-18.
237. Smith GE, Griffiths LA. (1974). Metabolism of N-acylated and O-alkylated drugs by the intestinal microflora during anaerobic incubation in vitro. Xenobiotica, 4, 477-487.
238. Smolensky MH, Haus E. (2001). Circadian rhythms and clinical medicine with applications to hypertension. Am J Hypertens, 14, 280S-290S.
239. Smolensky MH, Lemmer B, Reinberg AE. (2007). Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Adv Drug Deliv Rev, 59, 852-882.
240. Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW. (2008). The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm, 363, 1-25.
241. Spiller RC, Brown ML, Phillips SF. (1987). Emptying of the terminal ileum in intact humans. Influence of meal residue and ileal motility. Gastroenterology, 92, 724-729.
242. Staib AH, Loew D, Harder S, Graul EH, Pfab R. (1986). Measurement of theophylline absorption from different regions of the gastrointestinal tract using a remote controlled drug delivery device. Eur J Clin Pharmacol, 30, 691-697.
243. Staib AH, Woodcock BG, Loew D, Schuster O. (1989). Novel Drug Delivery and Its Therapeutic Applications. Chichester, UK: John Wiley.
244. Stark K, Guengerich FP. (2007). Characterization of orphan human cytochromes P450. Drug Metab Rev, 39, 627-637.
245. Stocco G, Cheok M, Crews K, Dervieux T, French D, Pei D, Yang W, Cheng C, Pui CH, Relling M, Evans W. (2009). Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther, 85, 164-172.
246. Strong HA, Renwick AG, George CF, Liu YF, Hill MJ. (1987). The reduction of sulphinpyrazone and sulindac by intestinal bacteria. Xenobiotica, 17, 685-696.
247. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y. (1996). Enteral absorption of insulin in rats from mucoadhesive chitosan- coated liposomes. Pharm Res, 13, 896-901.
248. Takimoto CH, Thomas R. (2000). The clinical development of 9-aminocamptothecin. Ann N Y Acad Sci, 922, 224-236.
249. Teitelbaum D, Arnon R, Sela M. (1999). Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proc Natl Acad Sci USA, 96, 3842-3847.
250. Teshima D, Hino B, Makino K, Yano T, Itoh Y, Joh Y, Iida M, Oishi R. (2003). Sulphasalazine-induced leucopenia in a patient with renal dysfunction. J Clin Pharm Therap, 28, 239-242.
251. Thorn M, Finnstrom N, Lundgren S, Rane A, Loof L. (2005). Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol, 60, 54-60.
252. Toshina K, Hirata I, Maemura K, Sasaki S, Murano M, Nitta M, Yamauchi H, Nishikawa T, Hamamoto N, Katsu K. (2000). Enprostil, a prostaglandin-E-2 analogue, inhibits interleukin-8 production of human colonic epithelial cell lines. Scand J Immunol, 52, 570-575.
253. Tozaki H, Emi Y, Horisaka E, Fujita T, Yamamoto A, Muranishi S. (1997a). Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: implications in peptide delivery to the colon. J Pharm Pharmacol, 49, 164-168.
254. Tozaki H, Komoike J, Tada C, Maruyama T, Terabe A, Suzuki T, Yamamoto A, Muranishi S. (1997b). Chitosan capsules for colonspecific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci, 86, 1016-1021.
255. Trevaskis NL, Charman WN, Porter CJ. (2008). Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev, 60, 702-716.
256. Tubic-Grozdanis M, Hilfinger J, Amidon G, Kim J, Kijek P, Staubach P, Langguth P. (2008). Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm Res, 25, 1591-1600.
257. Tuleu C, Basit AW, Waddington WA, Ell PJ, Newton JM. (2002). Colonic delivery of 4-aminosalicylic acid using amyloseethylcellulose- coated hydroxypropylmethylcellulose capsules. Aliment Pharmacol Therap, 16, 1771-1779.
258. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. (2004). Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit, 10, PI126-PI131.
259. Van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB, Jr., (2006). A phase II dose ranging, double-blind, placebocontrolled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther, 23, 1415-1425.
260. Van Dieren JM, Van Bodegraven AA, Kuipers EJ, Bakker EN, Poen AC, Van Dekken H, Nieuwenhuis EE, Van Der Woude CJ. (2009). Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis, 15, 193-198.
261. Vandamme TF, Lenourry A, Charrueau C, Chaumeil J. (2002). The use of polysaccharides to target drugs to the colon. Carbohydr Polym, 48, 219-231.
262. Varum FJ, Mcconnell EL, Sousa JJ, Veiga F, Basit AW. (2008). Mucoadhesion and the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst, 25, 207-258.
263. Vermeire S. (2006). Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment Pharmacol Ther, 24(Suppl 3), 2-10.
264. Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP. (2002). NOD2/ CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology, 123, 106-111.
265. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. (2002). Design of biodegradable particles for protein delivery. J Control Release, 78, 15-24.
266. Wadworth AN, Fitton A. (1991). Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs, 41, 647-664.
267. Walker S, Stiehl A, Raedsch R, Kloters P, Rudolph G. (1986). Colonic absorption of ursodeoxycholic acid (Urso) in man. Gastroenterology, 90, 1779.
268. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ. (2003). Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature, 421, 384-388.
269. Wang L, Chen W, Xie X, He Y, Bai X. (2008). Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. Exp Oncol, 30, 42-51.
270. Watanabe K, Yamashita S, Furuno K, Kawasaki H, Gomita Y. (1995). Metabolism of omeprazole by gut flora in rats. J Pharm Sci, 84, 516-517.
271. Watts P, Smith A. (2005). TARGIT technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract. Expert Opin Drug Deliv, 2, 159-167.
272. Weber WW, Hein DW. (1985). N-acetylation pharmacogenetics. Pharmacol Rev, 37, 25-79.
273. Weitschies W, Kosch O, Monnikes H, Trahms L. (2005). Magnetic Marker Monitoring: an application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked solid dosage forms. Adv Drug Deliv Rev, 57, 1210-1222.
274. Wielinga PR, Reid G, Challa EE, Van Der Heijden I, Van Deemter L, De Haas M, Mol C, Kuil AJ, Groeneveld E, Schuetz JD, Brouwer C, De Abreu RA, Wijnholds J, Beijnen JH, Borst P. (2002). Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol, 62, 1321-1331.
275. Wilding I. (2001). The enterion capsule: a novel technology for understanding the biopharmaceutical complexity of new molecular entities (NMEs). Drug Deliv Technol, 1, 23-24.
276. Wilding IR, Hardy JG, Sparrow RA, Davis SS, Daly PB, English JR. (1992). Invivo evaluation of enteric-coated naproxen tablets using gamma scintigraphy. Pharm Res, 9, 1436-1441.
277. Wilding IR, Davis SS, Sparrow RA, Smith KJ, Sinclair KA, Smith AT. (1993). The evaluation of an enteric-coated naproxen tablet formulation using gamma-scintigraphy. Eur J Pharm Biopharm, 39, 144-147.
278. Wilding IR, Connor AL, Carpenter P, Rordorf C, Branson J, Milosavljev S, Scott G. (2004). Assessment of lumiracoxib bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy. Pharm Res, 21, 443-446.
279. Williams CS, Mann M, Dubois RN. (1999). The role of cyclooxygenases in inflammation, cancer, and development. Oncogene, 18, 7908-7916.
280. Wilson CG, Washington N, Greaves JL, Kamali F, Rees JA, Sempik AK, Lampard JF. (1989). Bimodal release of ibuprofen in a sustainedrelease formulation: a scintigraphic and pharmacokinetic open study in healthy volunteers under different conditions of food intake. Int J Pharm, 50, 155-161.
281. Yang L, Watanabe S, Li J, Chu JS, Katsuma M, Yokohama S, Fix JA. (2003). Effect of colonic lactulose availability on the timing of drug release onset in vivo from a unique colon-specific drug delivery system (CODES). Pharm Res, 20, 429-434.
282. Yoshisue K, Masuda H, Matsushima E, Ikeda K, Nagayama S, Kawaguchi Y. (2000). Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats. Drug Metab Dispos, 28, 1162-1167.
283. Zimmermann C, Gutmann H, Hruz P, Gutzwiller JP, Beglinger C, Drewe J. (2005). Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos, 33, 219-224.